PolyPid will announce Q2 2025 financial results on August 13, 2025, followed by a conference call.
Quiver AI Summary
PolyPid Ltd., a late-stage biopharmaceutical company focused on enhancing surgical outcomes, has announced it will release its second quarter 2025 financial results and operational highlights on August 13, 2025, before U.S. market opening. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss these results and update stakeholders on business operations. PolyPid's lead product candidate, D-PLEX100, aimed at preventing abdominal colorectal surgical site infections, is on track for a New Drug Application submission in early 2026. The company employs proprietary PLEX technology for the controlled delivery of therapeutics and has additional projects in oncology, obesity, and diabetes. For more information, visit their website.
Potential Positives
- PolyPid is set to report its second quarter 2025 financial results and operational highlights, indicating ongoing transparency and accountability to investors.
- The upcoming conference call and webcast provide an opportunity for stakeholders to engage directly with management, fostering better investor relations.
- The preparation for New Drug Application (NDA) submission of D-PLEX100 for preventing surgical site infections signifies a significant milestone towards market introduction and commercialization of its lead product candidate.
- Positive phase 3 results have been achieved for D-PLEX100, enhancing investor confidence and validating the company's product development efforts.
Potential Negatives
- The announcement of an upcoming financial results report and conference call may highlight uncertainty or lack of clarity regarding the company's current financial health, particularly given its late-stage status in the biopharma industry.
- Relying heavily on forward-looking statements indicates that there are inherent risks and uncertainties associated with the company's future performance, potentially leading to investor skepticism.
- There is no definitive timeline provided for the expected NDA submission of D-PLEX100, which could raise concerns regarding the company's operational momentum and planning.
FAQ
When will PolyPid announce its Q2 2025 financial results?
PolyPid will report its second quarter 2025 financial results on August 13, 2025, before U.S. market opens.
What time is the PolyPid conference call?
The conference call is scheduled for 8:30 AM Eastern Time on August 13, 2025.
How can I access the PolyPid webcast?
You can access the PolyPid webcast at this link: https://edge.media-server.com/mmc/p/aqeywg9m.
What is PolyPid's lead product candidate?
PolyPid's lead product candidate is D-PLEX100, aimed at preventing abdominal colorectal surgical site infections.
Where can I find more information about PolyPid?
For additional information, visit PolyPid's official website at http://www.polypid.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PYPD Hedge Fund Activity
We have seen 2 institutional investors add shares of $PYPD stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC added 253,727 shares (+27.0%) to their portfolio in Q2 2025, for an estimated $895,656
- STONEPINE CAPITAL MANAGEMENT, LLC removed 48,693 shares (-47.0%) from their portfolio in Q1 2025, for an estimated $131,958
- CITADEL ADVISORS LLC added 10,558 shares (+inf%) to their portfolio in Q1 2025, for an estimated $28,612
- ROSALIND ADVISORS, INC. removed 4,500 shares (-0.4%) from their portfolio in Q1 2025, for an estimated $12,195
- TD WATERHOUSE CANADA INC. removed 781 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,116
- UBS GROUP AG removed 4 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $10
- MORGAN STANLEY added 0 shares (+0.0%) to their portfolio in Q1 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PYPD Analyst Ratings
Wall Street analysts have issued reports on $PYPD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Roth Capital issued a "Buy" rating on 06/18/2025
- JMP Securities issued a "Market Outperform" rating on 06/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/09/2025
To track analyst ratings and price targets for $PYPD, check out Quiver Quantitative's $PYPD forecast page.
$PYPD Price Targets
Multiple analysts have issued price targets for $PYPD recently. We have seen 4 analysts offer price targets for $PYPD in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Boobalan Pachaiyappan from Roth Capital set a target price of $9.0 on 06/18/2025
- Roy Buchanan from JMP Securities set a target price of $14.0 on 06/17/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $13.0 on 06/09/2025
Full Release
PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
|
Date:
|
Wednesday, August 13, 2025
|
| Time: | 8:30 AM Eastern Time |
| Conference Call: |
https://register-conf.media-server.com/register/BI24f4e2ebaf86432084ad872a4496f74d |
| Webcast: | https://edge.media-server.com/mmc/p/aqeywg9m |
About PolyPid
PolyPid Ltd. (Nasdaq:
PYPD
) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX
100
, PolyPid’s lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn .
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing of the NDA submission. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
[email protected]
Investor & IR Contact:
Arx | Capital Markets
North American Equities Desk
[email protected]
